

Disease

Susceptibility to atypical hemolytic uremic syndrome- 5^{1, 2}

Gene

C3

Inheritance	AD
Current Treatments	Eculizumab, Ravulizumab, Plasma infusion or exchange
Evidence for Treatment	guideline ³
Non-Molecular Testing Availability	no
Disease Frequency (per 100,000)	0.2 ⁴
Genes Included in Disease Frequency	C3, CFH, CFI, THBD, CD46, CFB, CFHR1
Experimental / Investigational Therapies	https://clinicaltrials.gov/ct2/results?cond=Atypical+Hemolytic+Uremic+Syndrome&term=&cntry=&state=&

References

- ¹ <https://www.ncbi.nlm.nih.gov/books/NBK1367/>
- ² <https://pubmed.ncbi.nlm.nih.gov/33048203/>
- ³ <https://pubmed.ncbi.nlm.nih.gov/31935318/>
- ⁴ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198674/>